Introduction {#Sec1}
============

The need for consilience or unity of knowledge from different fields is best exemplified in the field of sarcopenia of liver disease. Knowledge from hepatology, gerontology, nutrition, muscle biology, developmental biology, transplant surgery, epidemiology, molecular biology, physiology, and metabolism need to be integrated to improve our understanding of the mechanisms of loss of skeletal muscle mass in cirrhosis. Loss of skeletal muscle mass or sarcopenia is the most common complication of cirrhosis and adversely affects survival, quality of life, outcome after liver transplantation, and response to stress including infection and surgery \[[@CR1]\]. Cachexia and sarcopenia are recognized as a major complication of a number of chronic diseases including cancer, chronic obstructive pulmonary disease, chronic heart failure, and chronic renal failure \[[@CR1]--[@CR4]\]. It is interesting that there has been little focus on the prevalence, impact, consequences, and relative paucity of mechanistic targets or therapy of sarcopenia and cachexia in cirrhosis, especially given that the liver is the most metabolically active organ that regulates and interacts with the skeletal muscle and adipose tissue to form a "metabolic organ complex" \[[@CR5], [@CR6]\]. Cirrhosis is a form of end-stage liver disease that is the culmination of a number of chronic liver disorders. Since there is no therapy to reverse the fibrosis, hepatocellular dysfunction and vascular remodeling in cirrhosis, management has focused on treating the etiology of the liver disease, prevention and therapy of the complications, and replacing the diseased liver by transplantation. Few effective therapeutic modalities exist to treat the etiology of the disease and this contributes to the increase in incidence of cirrhosis \[[@CR7]--[@CR9]\]. Clinically, the most widely recognized complications include ascites, encephalopathy, portal hypertension with variceal bleeding, renal dysfunction, and hepatocellular carcinoma; however, the most frequent complication is malnutrition comprised of sarcopenia or loss of muscle mass and loss of fat mass or a combination constituting "hepatic cachexia". Prevention or management of complications of cirrhosis has been the mainstay of therapy in hepatology, but there has been inadequate focus on managing sarcopenia or cachexia in these patients \[[@CR10]\]. This is reflected by the lack of a clear definition of the components of malnutrition, the largely descriptive but not mechanistic studies, and the consequent lack of clear therapeutic strategies \[[@CR11]\]. Although, it is believed that liver transplantation is curative for cirrhosis, this therapeutic option does not exist for the majority of patients \[[@CR12]\]. Therefore, nontransplant therapeutic options remain the primary management option with the need to focus on reduced muscle mass because of its clinical relevance.

Malnutrition is the most frequent clinical problem in cirrhosis {#Sec2}
===============================================================

Data from the Centers for Disease Control in 2006 showed that the annual incidence of cirrhosis is 72.3 per 100,000 population with an annual mortality rate of 27,000 \[[@CR13]\]. Additional data support similar prevalence rates of cirrhosis both in the Western hemisphere and globally \[[@CR13]--[@CR18]\]. With the assumption of the baseline prevalence of 0.15 %, the total number of cirrhotics in the USA in 2006 is estimated to be 2.5 million. An alternative database search also yielded similar data from the VA system \[[@CR17], [@CR19]\]. Data were available from 2000 to 2007 and are shown in Fig. [1](#Fig1){ref-type="fig"} \[[@CR19]\]. These estimates further confirm the data from the organ procurement and transplant network that the prevalence of cirrhosis is progressively increasing based on the new patients added to the active and inactive waiting lists. Given the background of these staggering numbers, it is important to underscore the fact that the increase in annual liver transplant rates (17.42 to 22.29/million population) has not kept pace with the increase in numbers of patients with cirrhosis (Scientific Registry of Transplant Recipients (SRTR): 2009 OPTN/SRTR Annual Report 1999-2008. HHS/HRSA/HSB/DOT). Using the highest liver transplantation rate of 22.29/million (in 2006), the number of nontransplanted cirrhotics would increase by about 14,000/year based on the US population assumption of 300 million, without taking into account the projected increases related to hepatitis C and nonalcoholic fatty liver disease \[[@CR7], [@CR8], [@CR14]\]. Using these very conservative figures, the nontransplant management of cirrhosis will be required for over 2.5 million patients by the end of this decade. The goals of this approach are to increase transplant free survival, decrease the risks of complications, and improve quality of life especially since a reduced post transplant quality of life is being increasingly recognized \[[@CR11], [@CR20]--[@CR22]\].Fig. 1Annual number of patients diagnosed with cirrhosis in the VA system and the annual liver transplants done in the USA \[[@CR17], [@CR19]\]. If the total number of patients with cirrhosis diagnosed each year is assumed to follow the VA system, then the widening gap between these two graphs depicts the number of cirrhotics who are not transplanted and therefore need nontransplant therapeutic options. This gap has continued to widen over the past decade and is anticipated to follow this pattern till 2020. Data compiled from OPTN / SRTR 2009 Annual Data Report. HHS/HRSA/HSB/DOT. <http://optn.transplant.hrsa.gov/ar2009/data_tables_section9.htm>

Transplant free survival depends on the severity of the underlying liver disease as well as management of the complications of cirrhosis \[[@CR23]\]. Malnutrition has been reported in 60--80 % of patients with cirrhosis, but when sarcopenia was specifically evaluated, it occurred in about 40 % of cirrhotics \[[@CR24], [@CR25]\]. Esophageal varices are present in 30--60 % of patients with cirrhosis. Refractory ascites occurs in 5--10 % of patients and spontaneous bacterial peritonitis occurs in about 30 % of patients with ascites \[[@CR23]\]. Hepatorenal syndrome occurs in about 8 % of cirrhotic patients with ascites. Portopulmonary hypertension and hepatopulmonary syndrome occur in about 0.5--5 % of cirrhotics. The annual incidence of hepatocellular carcinoma is 1.4 % in compensated and 4 % in decompensated cirrhosis. Extensive studies have been published on these complications as of September 30, 2011 and the unfiltered numbers of human studies published and indexed in PUBMED are shown in Table [1](#Tab1){ref-type="table"}. As can be seen, the number of publications on sarcopenia in cirrhosis is very small and if the search term is expanded to cachexia or malnutrition, the number of publications is higher but the studies are no longer specific to muscle loss.Table 1Number of publications retrieved on PUBMED using the search terms limited for "human"Search termNumber of publications on PUBMEDCirrhosis, ascites5,633Cirrhosis, hepatic encephalopathy2,870Cirrhosis, portal hypertension8,675Cirrhosis, hepatocellular carcinoma11,963Cirrhosis, sarcopenia8Liver, sarcopenia16Cirrhosis, liver, cachexia46Cirrhosis, liver, malnutrition1,000

Malnutrition and its specific components in cirrhosis {#Sec3}
=====================================================

The major problems with the term "malnutrition in cirrhosis" is the lack of focus on the specific components that constitute malnutrition, i.e., sarcopenia, loss of visceral or subcutaneous adipose tissue mass, alteration in substrate utilization and disordered energy metabolism, and a combination to varying extent of these disorders. One definition for malnutrition that has been proposed is that it is "a state of nutrition in which a deficiency or excess (or imbalance) of energy, protein and other nutrient causes adverse effects on body composition, function and outcome" \[[@CR26]\]. The limitation of this definition is that it lacks specifics when it comes to the definition or terminology, especially in the background of advanced liver disease. Recent attempts to arrive at a consensus definition for sarcopenia, cachexia, and precachexia have focused on nonhepatic diseases, aging, and cancers. However, these definitions and the underlying mechanisms may need to be modified in patients with cirrhosis.

A number of complex metabolic alterations occur in liver disease that are unique to cirrhosis and affect the skeletal muscle growth and atrophy responses. These include dysregulation of fatty acid oxidation and ketogenesis, gluconeogenesis from amino acids, glycogenolysis, and selective utilization of aromatic amino acids in the liver and branched chain amino acids in the skeletal muscle as a source of energy \[[@CR27], [@CR28]\]. A number of biochemical, cytokine, hormonal, and neurological abnormalities in advanced liver disease are also similar to those in other chronic disorders \[[@CR29]\]. Therefore, it is essential to have a consensus definition for the terms precachexia, cachexia, and sarcopenia in cirrhotic patients that has common features with other chronic diseases and certain essential differences. Inclusion of patients with cirrhosis while such definitions are being generated will assist in both consilience and translation of the rapid advances occurring in the field of myology and nutrition into clinical application for these patients. *Sarcopenia* is characterized by loss of muscle mass and has been used to define the loss of muscle mass in aging even though it is now being used in other disease states. *Cachexia* is defined as loss of both fat and muscle mass \[[@CR6], [@CR30]--[@CR32]\]. Additional terms that have been used include *precachexia* that is defined by the unintentional weight loss of [\<]{.ul}5 % of usual body weight in the last 6 months, in the background of an underlying chronic disease, while *sarcopenic obesity* is used to refer to the disproportionate loss of muscle mass in the presence of increased adipose tissue mass \[[@CR5], [@CR32]\]. Missing are clear generalizable definitions and establishment of normal values. Most publications use historical norms and younger subjects to define sarcopenia that may not necessarily reflect the patient population \[[@CR33], [@CR34]\]. The potential of historical controls having different growth patterns, adipose tissue, and muscle mass in adulthood needs to be addressed. Additionally, the large-scale changes in the population demographics, mobility, and ethnicity are likely to affect the normative values. Furthermore, a recent comment that one of the hallmarks of cachexia is that loss of lean body mass cannot be prevented or reversed by simply increasing nutritional intake is of critical importance in the management of cirrhotic patients since neither cachexia nor sarcopenia is clearly defined in the cirrhotic population, but they do suffer from either or both \[[@CR35]\]. Given the absence of standardized terminology in patients with liver disease, there is a compelling need to define these terms taking into consideration, the metabolic abnormalities specific for cirrhosis. Finally, it must be reiterated that even though the signaling pathways responsible for regulation of skeletal muscle mass are altered, it is not clear if the same alterations occur in all chronic noncommunicable diseases \[[@CR36], [@CR37]\].

Clinical impact of sarcopenia, cachexia, and malnutrition in cirrhosis {#Sec4}
======================================================================

Since liver transplantation is not available or necessary for the majority of cirrhotics, nontransplant options are required and the end points for the therapy of these patients need to be redefined to improve quality of life, prevent and treat complications, and potentially extend survival \[[@CR12], [@CR13], [@CR21], [@CR22]\]. Using the published prevalence data, the total number of cirrhotic patients with reduced muscle mass is about 1.25 million. Sarcopenia is the most common complication of cirrhosis with very limited data on the mechanisms responsible for it and few treatment options (24). It contributes to the aggravation of other complications of cirrhosis including encephalopathy, ascites, and portal hypertension \[[@CR28], [@CR38]--[@CR43]\]. It is also the major contributor to impaired quality of life in these patients \[[@CR44]--[@CR47]\]. In contrast to the very limited literature on sarcopenia or muscle loss in liver disease \[[@CR24], [@CR25]\], there is an explosion of data on sarcopenia in aging and molecular mechanisms of regulation of muscle loss and re-growth \[[@CR30], [@CR48]--[@CR54]\]. Unfortunately, these very interesting and exciting advances in the field of muscle biology have had very limited translation into human cirrhosis. Our recent preliminary data that an increase in muscle mass \[[@CR55], [@CR56]\] is likely to improve survival provides an impetus for rapid translation to clinical use of many of the novel concepts in skeletal muscle loss including the role of satellite cells, autophagy, myostatin regulation of muscle mass, proteolytic pathways, metabolic regulation of muscle protein kinetics and the molecular regulation and integration of protein synthesis, breakdown, and satellite cell-mediated regeneration \[[@CR37], [@CR57], [@CR58]\].

Obese cirrhotic {#Sec5}
===============

An additional consideration in defining sarcopenia is the impact of weight loss and muscle loss in the obese cirrhotic \[[@CR59]--[@CR61]\]. While the traditional clinical profile of a patient with progressive worsening of liver disease is loss of muscle and adipose tissue mass, the clinical profile of patients with cirrhosis is changing with the rapid increase in the number patients with nonalcoholic fatty liver disease that occurs in the setting of obesity \[[@CR59], [@CR62]\]. The current focus on the management of the obese cirrhotic is to promote weight loss to prevent progression of the necro-inflammation and fibrosis of nonalcoholic fatty liver disease \[[@CR63]--[@CR65]\]. However, the benefit of weight loss in cirrhosis related to nonalcoholic fatty liver disease is as yet unknown \[[@CR63]\]. This is of clinical significance because of recent suggestions that overweight patients may have a better survival with chronic diseases classically associated with cachexia including those with advanced cancer, end-stage heart failure, renal failure on hemodialysis, and aging \[[@CR66], [@CR67]\]. The term "reverse epidemiology" has been applied to this paradox that unlike in the general population, overweight and obesity may not necessarily be detrimental to the short-term outcome in such patients \[[@CR67], [@CR68]\]. There are no data on the impact of obesity or weight loss in obese cirrhotic patients. Furthermore, it is also believed that in obese patients, a small weight loss can mask higher loss of skeletal muscle mass. This is especially important, since the end point of most clinical interventions is loss of whole body weight or body mass index, neither of which is a good measure of whole body skeletal muscle mass.

Aging cirrhotic {#Sec6}
===============

The aging of the population is accompanied by older cirrhotics. In fact, a review of the SRTR data (Fig. [2](#Fig2){ref-type="fig"}) showed that the most rapidly increasing population of patients with cirrhosis is over the age of 50 years. It is well recognized that the skeletal muscle mass in humans increases till the age of 20, is stable between 20 and 50, and after the age of 50 years, there is approximately a 1 % loss of muscle mass \[[@CR69], [@CR70]\]. This rapidly increasing population of older cirrhotics waiting for transplantation is likely to suffer from the combined effects of aging and cirrhosis on reduced muscle mass and consequent complications and adverse outcomes. A significant proportion of patients remain on the transplant waitlist (OPTN / SRTR 2009 Annual Data Report. HHS/HRSA/HSB/DOT) for prolonged periods of time (Fig. [3](#Fig3){ref-type="fig"}) and this adds to the burden of cirrhotic.sarcopenia.Fig. 2Numbers of patients with cirrhosis who are being placed on the liver transplant list annually and are active on the waiting list. Patients aged 50 years or more are forming the most rapidly increasing population of waitlisted patients on the transplant list. These patients are likely to have more sarcopenia due to the combined effects of aging and cirrhosis. Data compiled from OPTN / SRTR 2009 Annual Data Report. HHS/HRSA/HSB/DOT. <http://optn.transplant.hrsa.gov/ar2009/data_tables_section9.htm>

Post-transplant immunosuppressant effects {#Sec7}
=========================================

The most rapidly increasing immunosuppressive regimen being used for maintenance therapy after liver transplantation is noncalcineurin inhibitors like sirolimus and everolimus (Fig. [4](#Fig4){ref-type="fig"}). The impact of these mTOR inhibitors on muscle protein synthesis and autophagy is well known \[[@CR71], [@CR72]\]. However, their role in post-transplant skeletal muscle recovery has not been studied. Furthermore, their contribution to the post-liver transplant metabolic syndrome and development of sarcopenic obesity are also not known and need detailed human studies \[[@CR73]\]. Additionally, calcineurin is required for skeletal muscle differentiation, hypertrophy, and fiber-type determination \[[@CR74]\]. With the nearly universal use of calcineurin inhibitors after liver transplantation, the confounding effects of these on the reversal of pre-transplant sarcopenia is not known. It is therefore evident that post-transplantation immunomodulation is likely to affect the anticipated benefits after liver transplantation.Fig. 3Waiting time on the active liver transplant list has not changed significantly over the past decade. Continued waiting increases the age of the patient and the severity of disease, both of which worsen sarcopenia and muscle function. Data compiled from OPTN / SRTR 2009 Annual Data Report. HHS/HRSA/HSB/DOT. <http://optn.transplant.hrsa.gov/ar2009/data_tables_section9.htm>Fig. 4Use of mTOR and calcineurin inhibitors as maintenance immunosuppression after liver transplantation. This does not include the use of steroids alone which also contributes to sarcopenia. mTOR inhibitors result in impaired muscle protein synthesis as well as autophagy, both of which could aggravate sarcopenia after liver transplantation. Data compiled from OPTN / SRTR 2009 Annual Data Report. HHS/HRSA/HSB/DOT. <http://optn.transplant.hrsa.gov/ar2009/data_tables_section9.htm>

Potential mechanisms of sarcopenia and cachexia in cirrhosis {#Sec8}
============================================================

Metabolic studies show altered whole body protein turnover in cirrhosis {#Sec9}
-----------------------------------------------------------------------

As mentioned earlier, studies to date have used isotopic tracer methodology and descriptive and correlation studies to explain the development of "malnutrition" in cirrhosis. Isotopic tracer studies have shown that whole body protein breakdown is increased, unaltered, or decreased \[[@CR75]--[@CR79]\]. Indirect measures of whole body protein synthesis have been either unaltered or decreased \[[@CR77]--[@CR80]\]. Additionally, rates of albumin synthesis that have been used in other chronic disorders are a poor measure of nutrient response since albumin is synthesized in the liver and has limited value as a measure of nutritional response to substrate administration \[[@CR78]\].

Impact of complications of cirrhosis on protein turnover {#Sec10}
--------------------------------------------------------

Plasma concentrations of branched chain amino acids are reduced in cirrhosis and this may have a negative impact on skeletal muscle protein synthesis and breakdown \[[@CR81], [@CR82]\]. As mentioned earlier, complications of cirrhosis have an adverse impact on skeletal muscle mass and energy metabolism in cirrhosis. Following gastrointestinal bleeding, a large protein load deficient in isoleucine that results in enhanced amino acid oxidation, further reduction in plasma, and muscle amino acid pools contribute to the sarcopenia. This has major clinical implications with the potential use of isoleucine supplementation during gastrointestinal bleeding to prevent worsening muscle mass induced by gastrointestinal bleeding. Other complications including infection and encephalopathy also have the potential to aggravate skeletal muscle proteolysis and impaired protein synthesis in cirrhosis.

Etiology of cirrhosis and reduced muscle mass {#Sec11}
---------------------------------------------

Cirrhosis develops following chronic liver disease due to a number of etiologies that have been recognized to affect skeletal and fat mass. Among cirrhotics, the most severe loss of body protein, muscle area, and function has been reported in those with alcohol related and cholestatic diseases \[[@CR83]--[@CR85]\]. Alcohol has a direct adverse effect on skeletal muscle protein turnover and increased expression of myostatin \[[@CR86]\]. Bile salts have been reported to increase muscle oxygen consumption and energy expenditure \[[@CR87]\]. Since cirrhosis is a state of accelerated starvation, increased energy expenditure is likely to further impair protein synthesis and accelerate proteolysis.

Molecular mechanisms responsible for sarcopenia of cirrhosis {#Sec12}
------------------------------------------------------------

Data on the skeletal muscle signaling pathways regulating protein synthesis and breakdown have been identified but not studied in cirrhosis \[[@CR37]\]. Satellite cell biology has been extensively evaluated and its contributory role in sarcopenia of aging identified \[[@CR88]\]. However, there are no studies that have examined the role of impaired satellite cell function in human cirrhotic sarcopenia. A number of reasons contribute to this including the limited interest due to lack of availability of successful therapy, lack of focus on quality of life, and the belief that liver transplantation as a therapeutic advance will correct all the adverse consequences of cirrhosis. Additionally, the coagulopathy that is almost universal in advanced liver disease has been believed to preclude obtaining muscle biopsies safely. Encephalopathy and ascites limit performing complex and prolonged studies and the heterogeneity of the etiology and stage of the disease are additional factors that have resulted in limited advances in our understanding of the mechanisms of sarcopenia and cachexia in cirrhosis. Finally, given the cross-translational nature of the problem, it is difficult to identify investigators with established expertise in hepatology, metabolism, and molecular and skeletal muscle biology. Notwithstanding these limitations, some advances have been made in this field and lay the foundation for a greater intellectual interaction between hepatologists, developmental biologists, and those with expertise in muscle biology.

The past decade has seen enormous advances in understanding the mechanisms of sarcopenia of aging as well as the regulatory pathways that govern skeletal muscle atrophy, growth, regeneration, and satellite cell function. Discovery of myostatin, a TGFβ superfamily member, and the cross talk between the canonical insulin-like growth factor 1 (IGF1)--Akt--mTOR signaling as well as the ubiquitin proteasome pathways need to be examined in the context of cirrhosis \[[@CR36], [@CR37]\]. Identification of mTOR regulation by nutrient sensor, AMP kinase, general control of nutrition derepressed (GCN2) as a leucine sensor, and identification of increased skeletal muscle autophagy as a potential contributor to loss of muscle mass as well as its protective role during nutrient starvation are very exciting advances that have not been examined in a disease state \[[@CR48], [@CR49], [@CR89]\]. Translation of the role of these signaling pathways in liver disease is likely to contribute to identification of potential therapeutic targets that is likely to result in the development of novel therapeutic measures to reverse sarcopenia and cachexia in cirrhosis.

In contrast to the sarcopenia of cirrhosis, other systemic disorders and aging are also accompanied by sarcopenia with consequent reduced survival and quality of life (Table [2](#Tab2){ref-type="table"}) \[[@CR70], [@CR90]--[@CR102]\]. The predominant mechanism(s) in these disorders has been an increased proteasome-mediated proteolysis with a lesser contribution from reduced protein synthesis. With aging, there is also a significant contribution of impaired satellite cell function. This has also been shown by us in an animal model with portosystemic shunting but not evaluated in other disease states.Table 2Sarcopenia in other conditions compared to cirrhotic patientsAging \[[@CR70]\]Immobilization \[[@CR90], [@CR91]\]Cardiac failure \[[@CR92], [@CR93]\]COPD \[[@CR94]--[@CR96]\]Renal failure \[[@CR97]--[@CR99]\]Cancer \[[@CR101]\]Cirrhosis \[[@CR102]\]Prevalence20--40 %Nearly 100 %40--60 %60--80 %60--80 %70--80 %95 %Primary mechanismReduced synthesisIncreased proteasome-mediated proteolysisReduced synthesis, increased proteasome-mediated proteolysisIncreased proteasome-mediated proteolysisIncreased proteasome-mediated proteolysisReduced protein synthesis, increased proteasome-mediated proteolysisImpaired protein synthesisClinical impactFrailty, reduced survival and quality of lifeQuality of life impairedReduced survival, impaired quality of lifeReduced survival and impaired quality of lifeReduced survivalReduced survivalReduced survival, impaired quality of life, increased risk of other complications of cirrhosisMetabolic accompanimentsLow testosteroneLocal changesIncreased REE-Acidosis-Low branched chain amino acids, increased aromatic amino acids, low testosterone, elevated estradiolTherapeutic optionsExercise, increased protein intake esp. post exerciseExerciseExercise, protein intakeExercise, protein intakeExerciseIncreased protein intake, exerciseLate evening snack, branched chain amino acids especially leucine-enriched, no data on exercise*REE* resting energy expenditure; *COPD* chronic obstructive pulmonary diseaseFig. 5Potential mechanisms of sarcopenia due to impaired protein synthesis in cirrhosis and targeted interventions. Data compiled from OPTN / SRTR 2009 Annual Data Report. HHS/HRSA/HSB/DOT. <http://optn.transplant.hrsa.gov/ar2009/data_tables_section9.htm>

Therapeutic options and outcome measures {#Sec13}
========================================

Therapy for malnutrition in cirrhosis has focused on altering the hormonal and metabolic abnormalities of cirrhosis with very limited success. These have included growth hormone, insulin-like growth factor, testosterone, branched chain amino acid replacement, and late evening snack \[[@CR103]--[@CR105]\]. Quantifying the effectiveness of therapy requires precise outcome measures. Since skeletal muscle mass and strength have been related to survival and quality of life in cirrhosis as well as other chronic disorders with sarcopenia, studies that focus on such definite measures are necessary \[[@CR24], [@CR25], [@CR83], [@CR106], [@CR107]\]. Once again, the outcome measures do not focus on reversal of sarcopenia, and limitations of the outcome measures for malnutrition in cirrhosis include the development of ascites and whole body volume overloading, sodium retention, changes in plasma and muscle amino acid concentrations, hyper- and hypometabolism in over 30 % of patients, and the use of lean body mass as a surrogate for skeletal muscle mass. Initial suggestions that low expression of skeletal muscle IGF1 was followed by therapeutic intervention studies using IGF1-IGF1 binding protein complex with limited benefit \[[@CR103], [@CR104], [@CR108]--[@CR110]\]. Recently, we have shown that an increased expression of skeletal muscle myostatin is responsible for reduced muscle protein synthesis and impaired satellite cells in a rat model of portosystemic shunting \[[@CR56]\]. We have also shown that the adverse consequences of increased myostatin expression can be reversed without impacting the underlying liver disease which is especially exciting because of the aforementioned data that liver transplantation is not a universally available treatment option and reversing "hepatic cachexia--sarcopenia" can be a major therapeutic option for cirrhosis.

Nutriceuticals in sarcopenia of cirrhosis {#Sec14}
-----------------------------------------

The novel field of nutriceuticals has been shown to be effective in countering sarcopenia of aging \[[@CR111]--[@CR113]\]. These data have enormous application in patients with cirrhosis and systematic studies with defined outcome measures in reversal of sarcopenia and skeletal muscle function are needed. Use of leucine-enriched essential amino acids to stimulate mTOR independent of upstream inhibitors including myostatin and AMPK has been shown to be effective in other disorders with muscle atrophy \[[@CR113]--[@CR115]\]. Previous studies on branched amino acid supplementation in patients with cirrhosis have focused on their benefit in encephalopathy with nitrogen balance as a secondary outcome measure (Table [3](#Tab3){ref-type="table"}) \[[@CR116]--[@CR123]\]. It is interesting that the focus of amino acid supplementation in cirrhosis is based on the lower plasma-branched chain amino acids suggesting that administering these amino acids would result in improvement in outcome. However, since sarcopenia in cirrhosis as in other conditions with anabolic resistance is believed to be due to impaired mTOR signaling response, it can potentially be overcome by leucine-enriched supplementation with amino acids \[[@CR124]--[@CR126]\]. When branched chain amino acids are administered, stimulation of protein synthesis by leucine is likely to result in increased utilization of other essential amino acids that may then become limiting for protein synthesis. Even though this has not been specifically evaluated in patients with cirrhosis, the alteration in plasma amino acid profile in response to branched chain versus balanced amino acids lends credence to this view \[[@CR127]\]. This can be overcome by administering a balanced mixture of essential amino acids with leucine enrichment. Plasma concentrations of aromatic amino acids in cirrhosis are elevated and have been suggested to play a role in the development of hepatic encephalopathy \[[@CR81]\]. Therefore, studies to determine the optimum concentration of appropriate amino acid supplementation to derive the maximum skeletal muscle protein response in cirrhotics are necessary. Furthermore, glutamine is a conditionally essential amino acid in cirrhosis and has been shown to directly suppress myostatin expression in muscle cells in vitro \[[@CR128], [@CR129]\]. The role of glutamine supplementation in addition to leucine may reverse the molecular abnormalities of increased myostatin and mTOR resistance in cirrhosis to maximize the beneficial effects. Extracellular rather than intracellular concentrations of amino acids have been shown to be potent regulators of muscle protein metabolic response \[[@CR82]\]. Therefore, administration of the appropriate combination of essential amino acids to alter plasma concentrations can be an effective therapy in these patients \[[@CR82], [@CR130]\]. The integration of metabolic studies, molecular signaling pathway analyses, and clinically meaningful outcome measures are necessary to have a direct impact on the survival, complications, and quality of life in patients with cirrhosis. Few studies have examined the impact of interventions on skeletal muscle mass or strength in cirrhotics \[[@CR131]\]. This is important because an increase in acute protein synthesis response does not always translate into an increase in muscle anabolism \[[@CR53], [@CR132]\]. Finally, the source of dietary proteins, the amino acid composition as well as the digestibility of different proteins and the age of the subject alter the muscle protein metabolic response \[[@CR112], [@CR133], [@CR134]\].Table 3Effect of oral branched chain amino acid treatment on nutritional outcome in cirrhosisAuthorNo.Treatment duration (days)Dose of BCAA (g)Outcome measureResultCommentsMcGhee \[[@CR116]\]41115Nitrogen balanceNegativeBoth groups 50 g/day proteinHorst \[[@CR117]\]372120--60Nitrogen balanceNegative20 g increase to 60, both groups achieved similar nitrogen balance without HEChristie \[[@CR118]\]8320--60Anthropometry, nitrogen balanceNegativeIncrease from 20 to 60 g, both groups similar change in nitrogen balanceSwart \[[@CR119]\]8512--28Nitrogen balanceNegativeHigher nitrogen balance with 60 or 80 g/day proteinFiaccadori \[[@CR120]\]422825Nitrogen balancePositiveBCAA mixture improved nitrogen balanceGuarnieri \[[@CR121]\]790--1200.45/kg bwNitrogen balancePositiveBCAA improved nitrogen balance compared to lipid--carbohydrate supplementEgberts \[[@CR122]\]2270.25/kg bwNitrogen balancePositiveGreater increase in semiquantitative nitrogen balance with BCAAMarchesini \[[@CR123]\]61900.24/kg bwNitrogen balancePositiveSemiquantitative nitrogen balance better with BCAA*BCAA* branched chain amino acid, *bw* body weight, *HE* hepatic encephalopathy

Role of exercise in cirrhotic patients {#Sec15}
--------------------------------------

The role of aerobic and resistance exercise on skeletal muscle insulin signaling, protein synthesis response, AMP kinase activity, and satellite cell function has been identified \[[@CR50], [@CR135]\]. However, fatigue, reduced maximum exercise capacity in cirrhotics, and the presence of complications including ascites, encephalopathy, and portal pressure have limited the translation of the data or the elegant designs of the studies performed in noncirrhotic patients \[[@CR136]--[@CR143]\]. Resistance exercise increases portal hypertension, and even transient increases in portal hypertension can result in catastrophic variceal bleeding and death \[[@CR144]\]. It is therefore critical that the data on the impact of exercise on muscle mass and function be translated very judiciously in cirrhotic patients.

Novel strategies to reverse cachexia including myostatin antagonists are also of clinical interest especially given recent data that myostatin may play a critical role in cirrhotic sarcopenia \[[@CR56], [@CR145]\]. Given the paucity of data, the understudied nature of the problem, sarcopenia in cirrhosis deserves to be recognized as an area of unmet need with the potential to improve the outcome of the large number of patients with cirrhosis. One potential strategy for development of novel and successful therapies is the need for consilience between the diverse and seemingly unrelated fields identified earlier. A putative therapeutic approach to sarcopenia in cirrhosis is suggested in Fig. [5](#Fig5){ref-type="fig"}.
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